Richard Johnson, MD: Who Might Benefit from Ozempic
Short excerpt from a YouTube interview (April 6, 2024) in which Richard Johnson, MD, discusses the clinical role of GLP-1 agonists (e.g., Ozempic). He characterizes them as not a perfect or universal solution (many patients cannot tolerate them and they are costly) but useful in select patients — for example, to reduce weight sufficiently to enable transplant eligibility, to possibly avoid bariatric surgery in severe morbid obesity, and to assist modest-weight-loss efforts. The interlocutor notes they can kickstart weight loss but questions long-term suitability.
More from Dr.
Hippocrates said, let thy food be thy medicine #obesity #metabolicsyndrome #lustig #shorts #health
Bill Wilson, MD: Why GLP-1 Drugs Are Overpriced—and How Compounding and Competition Could Fix It
Nitrosamine in Pharmaceutical Products? A Deep Dive into Risk Management by Ron Najafi, Ph.D.
The Subcellular Processes That Belie All Chronic Disease. The Hateful (or Grateful) Eight #lustig
Bill Wilson, MD: GLPs May Reverse Carb Syndrome—Helping Patients Reach Zero and Sustain with Diet
Why Everything You Knew About Obesity Is Wrong | Dr. Robert Lustig on Sugar & Metabolic Syndrome
Robert Lustig, MD: How Fructose Fuels Fatty Liver, Oxidative Stress, and Metabolic Disease #fructose
Robert Lustig, MD: The 3 Types of Fat Fueling Insulin Resistance and Disease #insulin resistance
Bill Wilson, MD: GLPs May Reverse CARB Syndrome. Helping Patients Reach Zero and Sustain with Diet